Hunan Er Kang Pharmaceutical (300267) — Net Asset Quality Index
Hunan Er Kang Pharmaceutical (300267) has a Net Asset Quality Index of 87.4% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥5.05 Billion minus total liabilities of CN¥634.44 Million yields net assets of CN¥4.42 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Hunan Er Kang Pharmaceutical total liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Hunan Er Kang Pharmaceutical Net Asset Quality Index Over Time (2008–2024)
This chart shows how Hunan Er Kang Pharmaceutical's Net Asset Quality Index has evolved across 17 annual periods from 2008 to 2024. As of June 2025, the index stands at 87.4%, representing net assets of CN¥4.42 Billion against total assets of CN¥5.05 Billion CNY. For live market cap and overall valuation, see market cap of Hunan Er Kang Pharmaceutical.
Annual Net Asset Quality Index for Hunan Er Kang Pharmaceutical (2008–2024)
The table below presents the year-by-year Net Asset Quality Index for Hunan Er Kang Pharmaceutical from 2008 to 2024, covering 17 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Hunan Er Kang Pharmaceutical strategic capital allocation to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 84.7% | CN¥4.40 Billion | CN¥5.20 Billion | CN¥797.54 Million | ▼ -3.1 pp |
| 2023 | 87.8% | CN¥4.81 Billion | CN¥5.48 Billion | CN¥669.05 Million | ▲ +1.5 pp |
| 2022 | 86.3% | CN¥5.05 Billion | CN¥5.86 Billion | CN¥804.57 Million | ▼ -3.5 pp |
| 2021 | 89.7% | CN¥4.87 Billion | CN¥5.43 Billion | CN¥558.28 Million | ▲ +1.2 pp |
| 2020 | 88.5% | CN¥5.79 Billion | CN¥6.55 Billion | CN¥753.22 Million | ▼ -5.8 pp |
| 2019 | 94.3% | CN¥5.79 Billion | CN¥6.14 Billion | CN¥350.72 Million | ▲ +1.1 pp |
| 2018 | 93.2% | CN¥5.64 Billion | CN¥6.05 Billion | CN¥409.39 Million | ▼ -1.4 pp |
| 2017 | 94.6% | CN¥5.41 Billion | CN¥5.72 Billion | CN¥308.37 Million | ▲ +1.8 pp |
| 2016 | 92.8% | CN¥5.24 Billion | CN¥5.65 Billion | CN¥408.94 Million | ▲ +4.1 pp |
| 2015 | 88.7% | CN¥4.26 Billion | CN¥4.80 Billion | CN¥544.10 Million | ▲ +13.1 pp |
| 2014 | 75.6% | CN¥1.68 Billion | CN¥2.22 Billion | CN¥542.64 Million | ▼ -16.6 pp |
| 2013 | 92.2% | CN¥1.33 Billion | CN¥1.45 Billion | CN¥113.01 Million | ▼ -1.9 pp |
| 2012 | 94.1% | CN¥1.16 Billion | CN¥1.24 Billion | CN¥73.32 Million | ▼ -0.1 pp |
| 2011 | 94.2% | CN¥1.06 Billion | CN¥1.13 Billion | CN¥65.90 Million | ▲ +34.4 pp |
| 2010 | 59.7% | CN¥176.62 Million | CN¥295.77 Million | CN¥119.15 Million | ▲ +0.5 pp |
| 2009 | 59.2% | CN¥110.01 Million | CN¥185.73 Million | CN¥75.72 Million | ▲ +7.7 pp |
| 2008 | 51.5% | CN¥63.01 Million | CN¥122.38 Million | CN¥59.37 Million | — |